Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.22 USD | -1.28% | +6.90% | +0.42% |
Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.42% | 1.74B | C | ||
-9.59% | 7.67B | B- | ||
-1.20% | 5.26B | B | ||
+26.10% | 5.36B | C | ||
+0.02% | 4.57B | C | ||
-53.02% | 3.15B | D+ | ||
+6.42% | 2.59B | - | - | |
-14.95% | 2.06B | B- | ||
-8.29% | 1.79B | D+ | ||
+4.65% | 1.62B | - | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.